Receptor binding studies of soft anticholinergic agents

AAPS PharmSci

Volumn 3, Issue 4, 2001, Pages

  Huang, Fenglei ^a   Buchwald, Peter ^a   Browne, Clinton E ^a   Farag, Hassan H ^a   Wu, Whei Mei ^a   Ji, Fubao ^a   Hochhaus, Guenther ^a   Bodor, Nicholas ^a  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

Antagonists; Drug design; Drug evaluation; Metabolism; Muscarinic; Receptor binding; Soft drugs

Indexed keywords

(ALPHA CYCLOPENTYLPHENYL) 1 METHYLPYRROLIDINIUM CHLORIDE; (ALPHA CYCLOPENTYLPHENYL) 3 ACETOXYQUINUCLIDIUM CHLORIDE; (ALPHA CYCLOPENTYLPHENYL)METHYL 1,2 DIMETHYLPYRROLIDIUM CHLORIDE; (HYDROXYMETHYL) 3 DIISOPROPYLMETHYLAMMONIUM CHLORIDE 9 METHYLXANTHENE 9 CARBOXYLATE; 2 PHENYL 2 CYCLOHEXEN 1 CARBOXYL N,ALPHA ETHOXYCARBONYLMETHYLTROPINIUM METHYL SULFATE; 2 PHENYL 2 CYCLOHEXEN 1 CARBOXYL N,ALPHA METHOXYCARBONYLMETHYLTROPINIUM METHYLSULFATE; 2 PHENYL 2 CYCLOHEXEN 1 CARBOXYL N,BETA METHOXYCARBONYLMETHYLTROPINIUM BROMIDE; 2 PHENYL 2 CYCLOHEXEN 1 CARBOXYLY N,BETA ETHOXYCARBONYLMETHYLTROPINIUM BROMIDE; ATROPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; ETHOXYCARBONYLPHENYLCYCLOPENTYLACETYL N,N DIMETHYLTROPINIUM METHYL SULFATE; METHOXYCARBONYLPHENYLCYCLOPENTYLACETOXYETHYL N,N,N, TRIMETHYLAMMONIUM METHYL SULFATE; METHOXYCARBONYLPHENYLCYCLOPENTYLACETYL N,N DIMETHYLTOPINIUM METHYL SULFATE; METHOXYCARBONYLPHENYLCYCLOPETYLACETOXY N,N DIMETHYL 3 PYRROLIDINIUM METHYLSULFATE; METHYLSCOPOLAMINE; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; OCTANOL; PHENYLCYCLOPENTYL N,ALPHA ETHOXYCARBONYLMETHYLTROPINIUM METHYLSULFATE; PHENYLCYCLOPENTYL N,ALPHA METHOXYCARBONYLMETHYLTROPINIUM METHYLSULFATE; PHENYLCYCLOPENTYL N,BETA ETHOXYCARBONYLMETHYLTROPINIUM BROMIDE; PHENYLCYCLOPENTYL N,BETA METHOXYCARBONYLMETHYLTROPINIUM BROMIDE; PIRENZEPINE; PROPANTHELINE BROMIDE; RECEPTOR SUBTYPE; SCOPOLAMINE; TROPINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WATER;

ANIMAL EXPERIMENT; ANTICHOLINERGIC EFFECT; ARTICLE; BRONCHODILATATION; CONTROLLED STUDY; CORRELATION COEFFICIENT; DIPOLE; DRUG BINDING SITE; DRUG METABOLISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; ELECTRONICS; GASTROINTESTINAL DISEASE; GEOMETRY; GUINEA PIG; HUMAN; ILEUM CONTRACTION; LIGAND BINDING; LINEAR REGRESSION ANALYSIS; LIPOPHILICITY; MYDRIASIS; NONHUMAN; PARTITION COEFFICIENT; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SIDE EFFECT; TACHYCARDIA; VISUAL IMPAIRMENT; XEROSTOMIA;

EID: 0035783270     PISSN: 15221059     EISSN: None     Source Type: Journal    
DOI: 10.1208/ps030430     Document Type: Article

References (61)

1. Brown JH, Taylor P. Muscarinic receptor agonists and antagonists. In: Goodman LS, Gilman A, Hardman JG, Gilman AG, Limbird LE, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill; 1996:141-160.
2. Birkhimer LJ, Jacobson PA, Olson J, Goyette DM. Ocular scopolamine induced psychosis. J Fam Prac. 1984;18(3):464-469.
3. Fraunfelder FT. Mydriatics and cycloplegics. In: Drug Induced Ocular Side Effects & Drug Interactions. New York: Lea & Febiger; 1989:445-458.
4. Katzung B. Cholinoceptor-blocking drugs. In: Katzung B, ed. Basic & Clinical Pharmacology. Stamford, CT: Appleton & Lange; 1998:105-117.
5. Macmillan FSK, Reller H, Synder FHT. The antiperspirant action of topically applied anticholinergics. J Invest Dermatol. 1964;42:363-377.
6. Shelley WB, Horvath PN. Comparative study on the effect of anticholinergic compounds on sweating. J Invest Dermatol. 1951;16:267-274.
7. Stoughton RB, Chiu F, Fritsch W, Nurse D. Topical suppression of eccrine sweat delivery with a new anticholinergic agent. J Invest Dermatol. 1964;42:151-155.
8. Ji F, Huang F, Juhasz A, Wu W, Bodor N. Design, synthesis, and pharmacological evaluation of soft glycopyrrolate and its analog. Pharmazie. 2000;55(3):187-191.
9. Juhasz A, Huang F, Ji F, Buchwald P, Wu WM, Bodor N. Design and evaluation of new soft anticholinergic agents. Drug Dev Res. 1998;43:117-127.
10. Kumar GN, Bodor N. Soft anticholinergics. Curr Med Chem. 1996;3:23-36.
11. Bodor N, Buchwald P. Soft drug design: general principles and recent applications. Med Res Rev. 2000;20(1):58-101.
12. Bodor N. Novel approaches to the design of safer drugs: Soft drugs and site-specific chemical delivery systems. In: Testa B, ed. Advance in Drug Research. Orlando, FL: Academic Press; 1984:255-331.
13. Bodor N, Woods R, Raper C, Kearney P, Kaminski JJ. Soft drugs. 3. A new class of anticholinergic agents. J Med Chem. 1980;23(5):474-480.
14. Hammer RH, Wu W-M, Sastry JS, Bodor N. Short acting soft anticholinergics. Curr Eye Res. 1991;10:565-570.
15. Kumar GN, Hammer RH, Bodor NS. Soft drugs-XVI. Design, evaluation and transdermal penetration of novel soft anticholinergics based on methatropine. Bioorg Med Chem. 1993;1(5):327-332.
16. Caulfield MP. Muscarinic receptors-characterization, coupling and function. Pharmacol Ther. 1993;58(3):319-379.
17. 2 biochemical and functional characterization. Life Sci. 1982;31(26):2991-2998.
18. 2 muscarinic receptor subtypes. Life Sci. 1983;32(26):3001-3011.
19. Waelbroeck M, Tastenoy M, Camus J, et al. Binding and functional properties of antimuscarinics of the hexocyclium/sila-hexocyclium and hexahydro-diphenidol/hexahydro-sila-diphenidol type to muscarinic receptor subtypes. Br J Pharmacol. 1989;98(1):197-205.
20. 3 receptors. J Pharmacol Exp Ther. 1987;242(1):257-262.
21. Mutschler E, Lambrecht G. Selective muscarinic agonists and antagonists in functional tests. Trends Pharmacol Sci. 1984;5 (suppl.):39-44.
22. Bonner TI, Buckley NJ, Young AC, Brann MR. Identification of a family of muscarinic acetylcholine receptor genes. Science. 1987;237(4814):527-532.
23. Bonner TI, Young AC, Brann MR, Buckley NJ. Cloning and expression of the human and rat m5 muscarinic acetylcholine receptor genes. Neuron. 1988;1(5):403-410.
24. Peralta EG, Ashkenazi A, Winslow JW, Smith DH, Ramachandran J, Capon DJ. Distinct primary structures, ligand-binding properties and tissue-specific expression of four human muscarinic acetylcholine receptors. Embo J. 1987;6(13):3923-3929.
25. Buckley NJ, Bonner TI, Buckley CM, Brann MR. Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells. Mol Pharmacol. 1989;35(4):469-476.
26. Bolden C, Cusack B, Richelson E. Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells. J Pharmacol Exp Ther. 1992;260(2):576-580.
27. 1-m5) in rabbit peripheral tissues. Mol Pharmacol. 1991;40(4):459-462.
28. 4 binding sites in rabbit lung, chicken heart, and NG108-15 cells. Mol Pharmacol. 1990;38(6):805-815.
29. Dorje F, Wess J, Lambrecht G, Tacke R, Mutschler E, Brann MR. Antagonist binding profiles of five cloned human muscarinic receptor subtypes. J Pharmacol Exp Ther. 1991;256(2):727-733.
30. Barbier P, Renzetti AR, Turbanti L, et al. Stereoselective inhibition of muscarinic receptor subtypes by the eight stereoisomers related to rociverine. Eur J Pharmacol. 1995;290(2):125-132.
31. Wess J, Lambrecht G, Mutschler E, Brann MR, Dorje F. Selectivity profile of the novel muscarinic antagonist UH-AH 37 determined by the use of cloned receptors and isolated tissue preparations. Br J Pharmacol. 1991;102(1):246-250.
32. Waelbroeck M, Lazareno S, Pfaff O, et al. Stereoselective recognition of the enantiomers of phenglutarimide and of six related compounds by four muscarinic receptor subtypes. Br J Pharmacol. 1996;119(7):1319-1330.
33. Eglen RM, Waston N. Selective muscarinic receptor agonists and antagonists. Pharmacol Toxicol. 1996;78:59-68.
34. Grimm U, Moser U, Mutschler E, Lambrecht G. Muscarinic receptors: Focus on presynaptic mechanisms and recently developed novel agonists and antagonists. Pharmazie. 1994;49(10):711-726.
35. Hammer RH, Amin K, Gunes ZE, Brouillette G, Bodor N. Novel "soft" anticholinergic agents. Drug Des Deliv. 1988;2(3):207-219.
36. Brouillette G, Kawamura M, Kumar GN, Bodor N. Soft drugs. 21. Design and evaluation of soft analogs of propantheline. J Pharm Sci. 1996;85(6):619-623.
37. Cheng YC, Prusoff WH. Relationship between the inhibition constant (ki) and the concentration of inhibitor which causes 50 per cent inhibition (IC50) of an enzymatic reaction. Biochem Pharmacol. 1973;22:3099-3180.
38. Van Rossum JM, Hurkmans JH, Walters CJ. Cumulative dose response curves. Arch Int Pharmacodyn Therap. 1965;143:299-330.
39. Dewar MJS, Zoebisch EG, Healy EF, Stewart JJP. Am1: a new general purpose quantum mechanical molecular model. J Am Chem Soc. 1985;107:3902-3909.
40. Bodor N, Gabanyi Z, Wong C-K. A new method for the estimation of partition coefficient. J Am Chem Soc. 1989;111:3783-3786.
41. Bodor N, Buchwald P. Molecular size based approach to estimate partition properties for organic solutes. J Phys Chem B. 1997;101:3404-3412.
42. Buchwald P, Bodor N. Octanol-water partition: searching for predictive models. Curr Med Chem. 1998;5(5):353-380.
43. Moriguchi I, Hirono S, Liu Q, Nakagome I, Matsushita Y. Simple method of calculating octanol/water partition coefficient. Chem Pharm Bull. 1992;40:127-130.
44. Bodor N, Huang MJ. A new method for the estimation of the aqueous solubility of organic compounds. J Pharm Sci. 1992;81(9):954-960.
45. Buchwald P, Bodor N. Quantitative structure-metabolism relationships: steric and nonsteric effects in the enzymatic hydrolysis of noncongener carboxylic esters. J Med Chem. 1999;42(25):5160-5168.
46. Hulme EC, Birdsall NJ, Burgen AS, Mehta P. The binding of antagonists to brain muscarinic receptors. Mol Pharmacol. 1978;14(5):737-750.
47. Hulme EC, Berrie CP, Birdsall NJ, Burgen AS. Two populations of binding sites for muscarinic antagonists in the rat heart. Eur J Pharmacol. 1981;73(2-3):137-142.
48. Nathanson NM. Molecular properties of the muscarinic acetylcholine receptor. Annu Rev Neurosci. 1987;10:195-236.
49. Hochhaus G, Derendorf H. Dose optimization based on pharmacokinetic-pharmacodynamic modeling. In: Derendorf H, Hochhaus G, eds. Handbook of Pharmacokinetic/Pharmacodynamic Correlation. Boca Raton, FL: CRC Press; 1995:79-120.
50. Eglen RM, Reddy H, Watson N, Challiss RA. Muscarinic acetylcholine receptor subtypes in smooth muscle. Trends Pharmacol Sci. 1994;15(4):114-119.
51. Hammer RH, Gunes E, Kumar GN, Wu WM, Srinivasan V, Bodor NS. Soft drugs-XIV. Synthesis and anticholinergic activity of soft phenylsuccinic analogs of methatropine. Bioorg Med Chem. 1993;1(3):183-187.
52. 4. Eur J Pharmacol. 1990;189 (2-3):135-142.
53. Kumar G, Huang MJ, Hammer R, Bodor N. Soft drugs. 17: Quantitative structure-activity relationships of soft anticholinergics based on methatropine and methscopolamine [letter]. J Pharm Sci. 1994;83(1):117-118.
54. Banerjee S, Lien EJ. Quantitative correlations and reexamination of the importance of hydrophobic and steric factors in anticholinergic drug receptor interactions. Pharm Res. 1990;7(7):746-750.
55. Nilsson BM, Sundquist S, Johansson G, et al. 3-Heteroaryl-substituted quinuclidin-3-ol and quinuclidin-2-ene derivatives as muscarinic antagonists. Synthesis and structure-activity relationships. J Med Chem. 1995;38(3):473-487.
56. Nordvall G, Sundquist S, Johansson G, Glas G, Nilvebrant L, Hacksell U. 3-(2-Benzofuranyl)quinuclidin-2-ene derivatives: Novel muscarinic antagonists. J Med Chem. 1996;39(17):3269-3277.
57. Feriani A, Gaviraghi G, Toson G, et al. Cholinergic agents structurally related to furtrethonium. 2. Synthesis and antimuscarinic activity of a series of N-[5-[(1′-substituted-acetoxy) methyl]-2-furfuryl]dialkylamines. J Med Chem. 1994;37(25):4278-4287.
58. Xu R, Sim MK, Go ML. Synthesis, antimuscarinic activity and quantitative structure-activity relationship (QSAR) of tropinyl and piperidinyl esters. Chem Pharm Bull (Tokyo). 1998;46(2):231-241.
59. Recanatini M, Tumiatti V, Budriesi R, et al. Synthesis, muscarinic blocking activity and molecular modeling studies of 4-DAMP-related compounds. Bioorg Med Chem. 1995;3(3):267-277.
60. Huang F. Design, Synthesis, Pharmacokinetic, and Pharmacodynamic Evaluation of a New Class of Soft Anticholinergics [PhD thesis]. Gainesville: University of Florida; 1999.
61. Hansch C, Leo A, Hoekman D. Exploring QSAR. Hydrophobic, Electronic, and Steric Constants. Vol. 2. Washington, DC: American Chemical Society; 1995.